



Neuren (NEU) - ASX Announcement

29 December 2017

Non-executive director retirement

Melbourne, Australia, 29 December 2017: Neuren Pharmaceuticals (ASX: NEU) today announced that after serving for nearly 6 years, Bruce Hancox will retire as a non-executive director on 31 December 2017.

Neuren Executive Chairman Richard Treagus commented: "Bruce has provided valuable support, insight and expertise to the Neuren board since 2012, always remaining highly engaged and generous with his time. We are very grateful to Bruce and we extend our best wishes to him for the future."

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Neuren presently has trofinetide in Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development. Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia, correcting deficits in synaptic function and regulating oxidative stress response. The most advanced trofinetide program is for Rett syndrome, supported by rettsyndrome.org. Both the Rett syndrome and Fragile X syndrome programs have been granted Fast Track designation by the US Food and Drug Administration and have Orphan Drug designation in both the United States and the European Union.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

For more information, please contact:

Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com; +61 417 520 509